Reumatologia
Diretriz holandesa multidisciplinar sobre saúde ocupacional visando a aumentar a participação no trabalho entre pacientes com dor lombar e síndrome radicular lombossacral.
8 Out, 2021 | 11:37hRevisão sistemática | Exercício é uma terapia efetiva para tratar dor lombar de longa duração?
4 Out, 2021 | 10:00hResumo: Is exercise an effective therapy to treat long-lasting low back pain? – Cochrane Library
Estudo original: Exercise therapy for chronic low back pain – Cochrane Library
Comentário no Twitter
New @CochraneBack Cochrane review – 249 RCTs – ~25,000 participants – consistent, moderately strong evidence that #exercise treatment was more effective than no treatment or usual care for the management of chronic #backpain 📚 #systematicreview: https://t.co/X10rUtnNNb pic.twitter.com/O0AtZK2gZq
— Cochrane UK (@CochraneUK) October 2, 2021
Artigo de consenso | Indicações clínicas para procedimentos intervencionistas orientados por imagem no sistema musculoesquelético – Parte V: joelho.
27 Set, 2021 | 11:55hVer outros artigos da série: Consensus paper: Clinical indications for image-guided interventional procedures in the musculoskeletal system.
AAOS atualiza diretriz de prática clínica sobre osteoartrose do joelho.
27 Set, 2021 | 10:50hComunicado de imprensa: AAOS Updates Clinical Practice Guideline for Osteoarthritis of the Knee – American Academy of Orthopaedic Surgeons
Resumo da diretriz: Management of Osteoarthritis of the Knee (Non-Arthroplasty) (3rd Edition) – American Academy of Orthopaedic Surgeons
Artigo completo: Management of Osteoarthritis of the Knee (Non-Arthroplasty) Evidence-Based Clinical Practice Guideline
Diretriz de prática clínica KDIGO 2021 para o tratamento de doenças glomerulares.
27 Set, 2021 | 10:48hResumo executivo: KDIGO 2021 Guideline for the Management of Glomerular Diseases – Kidney Disease: Improving Global Outcomes
[Preprint] Estudo randomizado | Reforço vacinal com vacina heteróloga vs. homóloga em pacientes imunossuprimidos sem soroconversão de anticorpo contra SARS-CoV-2 após vacinação primária com vacina de mRNA.
12 Set, 2021 | 20:55h
Comentário no Twitter (fio – clique para saber mais)
Results of 60-person randomized trial of 3rd shot of mRNA or AZ vax in people on rituximab who didn't seroconvert after BNT-Pfizer (most) or Moderna vax. Found dose 3 reduced those with no humoral or cellular response from 31% to 6% …1/2 https://t.co/HIjeDaFy7w Preprint #IC
— Hilda Bastian, PhD (@hildabast) September 8, 2021
Revisão | Complicações musculoesqueléticas após doença crítica.
3 Set, 2021 | 12:37h
Comentário no Twitter
Very pleased that our scoping review on MSK complications following critical illness has been published – first paper from my PhD! @mawilliamsinOx @helendawes2 @matthewjrowland @ouh_therapies @MOReS_OBU #icurehab https://t.co/f6kHDtMzrj pic.twitter.com/bOm3YvLP5U
— Owen Gustafson (@OxfordICUPhysio) August 26, 2021
Função do diagnóstico por imagem na artrite psoriática: como, quando e por quê.
3 Set, 2021 | 12:35hRole of diagnostic imaging in psoriatic arthritis: how, when, and why – Insights into Imaging
Revisão | COVID-19 e doenças inflamatórias imunomediadas: efeitos da doença e do tratamento sobre os desfechos de COVID-19 e as respostas vacinais.
3 Set, 2021 | 11:17h
Comentário no Twitter
NEW REVIEW—COVID-19 and immune-mediated inflammatory diseases
Filippo Fagni and colleagues @UniFAU review the effect of disease and treatment on #COVID19 outcomes and #vaccine responseshttps://t.co/ue8XnDF1sM #LancetRheumatology @KorayTascilar pic.twitter.com/Yrk4SmeSbE
— The Lancet Rheumatology (@TheLancetRheum) August 27, 2021
Suplemento: o futuro dos inibidores seletivos JAK1 em reumatologia.
26 Ago, 2021 | 12:11hPágina principal: The future of JAK1 selective inhibitors – Rheumatology
How important is JAK1 selectivity?
JAK1: Number one in the family; number one in inflammation?
Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis
Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis
The safety of JAK-1 inhibitors
Clinical use of Jak 1 inhibitors for rheumatoid arthritis
JAK1 selective inhibitors for the treatment of spondyloarthropathies
JAK1 inhibition and inflammatory bowel disease